Abstract:Epidemiological studies established an association between chronic inflammation and higher risk of cancer. Inhibition of proteolytic enzymes represents a potential treatment strategy for cancer and prevention of cancer metastasis. Cathepsin C (CatC) is a highly conserved lysosomal cysteine dipeptidyl aminopeptidase required for the activation of pro-inflammatory neutrophil serine proteases (NSPs, elastase, proteinase 3, cathepsin G and NSP-4). NSPs are locally released by activated neutrophils in response to pathogens and non-infectious danger signals. Activated neutrophils also release neutrophil extracellular traps (NETs) that are decorated with several neutrophil proteins, including NSPs. NSPs are not only NETs constituents but also play a role in NET formation and release. Although immune cells harbor large amounts of CatC, additional cell sources for this protease exists. Upregulation of CatC expression was observed in different tissues during carcinogenesis and correlated with metastasis and poor patient survival. Recent mechanistic studies indicated an important interaction of tumor-associated CatC, NSPs, and NETs in cancer development and metastasis and suggested CatC as a therapeutic target in a several cancer types. Cancer cell-derived CatC promotes neutrophil recruitment in the inflammatory tumor microenvironment. Because the clinical consequences of genetic CatC deficiency in humans resulting in the elimination of NSPs are mild, small molecule inhibitors of CatC are assumed as safe drugs to reduce the NSP burden. Brensocatib, a nitrile CatC inhibitor is currently tested in a phase 3 clinical trial as a novel anti-inflammatory therapy for patients with bronchiectasis. However, recently developed CatC inhibitors possibly have protective effects beyond inflammation. In this review, we describe the pathophysiological function of CatC and discuss molecular mechanisms substantiating pharmacological CatC inhibition as a potential strategy for cancer treatment.

Synthesis and biological evaluation of selective pepstatin based trifluoromethylated inhibitors of Cathepsin D

Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors.

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

A Multifunctional Protease Inhibitor To Regulate Endolysosomal Function

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

New inhibitors of cathepsin V impair tumor cell proliferation and elastin degradation and increase immune cell cytotoxicity

Novel selective proline-based peptidomimetics for human cathepsin K inhibition

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Interactions of a Low Molecular Weight Inhibitor from Streptomyces sp. MBR04 with Human Cathepsin D: Implications in Mechanism of Inactivation

Advances in Cathepsin S Inhibition: Challenges and Breakthroughs in Drug Development

Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins

Cathepsin D inhibitors based on tasiamide B derivatives with cell membrane permeability

Molecular Modeling and Biological Effects of Peptidomimetic Inhibitors of TACE Activity.

Highly Selective Aza-Nitrile Inhibitors for Cathepsin K, Structural Optimization and Molecular Modeling

Design, synthesis, and bioactivities of tasiamide B derivatives as cathepsin D inhibitors.

Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity

Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes

Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells

Cathepsin C inhibition as a potential treatment strategy in cancer

In-silico assessment of novel peptidomimetics inhibitor targeting STAT3 and STAT4 N-terminal domain dimerization: A comprehensive study using molecular docking, molecular dynamics simulation, and binding free energy analysis

Design, Synthesis and Biological Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives As Aminopeptidase N/CD13 Inhibitors.